Aclaris Therapeutics Moves Forward with ATI-052 Development
Recently, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), based in Wayne, PA, announced a significant milestone in their development of ATI-052, a novel bispecific monoclonal antibody. The U.S. Food and Drug Administration has granted the company clearance for the Investigational New Drug (IND) application, paving the way for a Phase 1a/1b clinical trial that focuses on treating immuno-inflammatory diseases.
Dr. Hugh Davis, Aclaris’ President and Chief Operating Officer, emphasized the company's commitment to therapeutic innovation, stating that bispecific antibodies represent a transformative approach in immunotherapy. The agreement Aclaris has with Biosion, Inc. centers on ATI-052, which is designed to inhibit both the thymic stromal lymphopoietin (TSLP) ligand and the IL-4 receptor. This unique dual action addresses a key proinflammatory pathway that could alter the treatment landscape for various diseases.
Details on the Upcoming Clinical Trial
The upcoming clinical trial will be randomized, blinded, and placebo-controlled, aimed at evaluating single and multiple ascending doses of ATI-052. Following this, a proof-of-concept phase will be initiated for an undisclosed indication. Aclaris is anticipating the trial to start in the second quarter of 2025, marking a critical step forward in the clinical development of this promising therapy.
Understanding Bispecific Antibodies
One of the primary attributes of bispecific antibodies is their ability to bind to two different targets at the same time. This innovative design enables a more effective inhibition of pathways than traditional monoclonal antibodies, creating new possibilities for treating various immune-modulated conditions. Through ATI-052, Aclaris hopes to offer enhanced efficacy against diseases that currently lack adequate therapeutic options.
What is an Investigational New Drug Application?
An IND application is pivotal for any organization wishing to commence human trials of a new drug. It includes a wealth of information regarding the investigational drug, including its design, pharmacological profile, and protocols for the proposed clinical trial. The FDA's approval is vital for any entity to legally pursue clinical research in the United States.
About ATI-052: The Next Generation Antibody
ATI-052 stands out as a potential best-in-class bispecific monoclonal antibody specifically targeting TSLP and IL-4R. Its design not only blocks the upstream signaling of the TSLP receptor but also pays attention to inhibiting IL-4R activation—two critical pathways in the inflammatory process. This novel approach is anchored by the same TSLP antigen-binding fragment as Aclaris’ previous investigational antibody, ATI-045, which enhances its impact through increased binding affinity and extended half-life.
Aclaris Therapeutics: A Leader in Immuno-Inflammatory Treatments
Aclaris Therapeutics, Inc. is dedicated to addressing the unmet needs of patients suffering from immuno-inflammatory diseases. The company’s robust pipeline is fueled by a dynamic research and development engine, which continually seeks innovative solutions for conditions that currently present limited treatment options. More details about their work can be found directly on Aclaris’ official website, where they also maintain a presence on social media platforms for the latest updates.
Questions regarding media or investor relations can be directed to:
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
Frequently Asked Questions
What is ATI-052?
ATI-052 is a bispecific monoclonal antibody that targets TSLP and IL-4 receptors to treat immuno-inflammatory diseases.
When will the clinical trial for ATI-052 start?
Aclaris Therapeutics expects to initiate the Phase 1a/1b clinical trial in the second quarter of 2025.
What does an IND application entail?
An IND application involves detailed information regarding the investigational drug and seeks FDA approval to initiate human testing.
How do bispecific antibodies work?
Bispecific antibodies have the unique ability to bind to two different targets simultaneously, offering enhanced treatment efficacy compared to traditional antibodies.
Who can I contact for more information about Aclaris?
You can contact Will Roberts, Senior Vice President of Corporate Communications and Investor Relations, for inquiries regarding Aclaris Therapeutics.
